参考文献/References:
[1] Tritos NA,Biller BM,Swearingen B,et al. Management of Cushing disease[J]. Nat Rev Endocrinol,2011,7（5）：279-289.
[2] Pinchot S N,Sippel R,Chen H. ACTH-producing carcinoma of the pituitary with refractory Cushing's Disease and hepatic metastases：a case report and review of the literature[J]. World J Surg Oncol,2009,7：39.
[3] Stratakis CA,Tichomirowa MA,Boikos S,et al.The role of germline AIP,MEN1,PRKAR1A,CDKN1B and CDKN2C muta-tions in causing pituitary adenomas in a large cohort of children,adolescents,and patients with genetic syndromes[J].Clin Genet,2010,78（5）：457-463.
[4] Riminucci M,Collins MT,Lala R, et al.An R201H activating mutation of the GNAS1（Gsalpha） gene in a corticotroph pituitary adenoma[J]. Mol Pathol,2002,55（1）：58-60.
[5] Salehi F,Kovacs K,Scheithauer BW,et al. Immunohistochemical expression of pituitary tumor transforming gene（PTTG） in pituitary adenomas：a correlative study of tumor subtypes[J]. Int J Surg Pathol,2010,18（1）：5-13.
[6] Jia W,Lu R,Jia G,et al. Expression of pituitary tumor transforming gene （PTTG） in human pituitary macroadenomas[J]. Tumour Biol,2013,34（3）：1559-1567.
[7] Roussel-Gervais A,Bilodeau S,Vallette S,et al. Cooperation between cyclin E and p27（Kip1） in pituitary tumorigenesis[J]. Mol Endocrinol,2010,24（9）：1835-1845.
[8] Bellodi C,Krasnykh O,Haynes N,et al. Loss of function of the tumor suppressor DKC1 perturbs p27 translation control and contributes to pituitary tumorigenesis[J]. Cancer Res,2010,70（14）：6026-6035.
[9] Tateno T,Izumiyama H,Doi,M et al. Differential gene expres-sion in ACTH-secreting and non-functioning pituitary tumors[J]. Eur J Endocrinol,2007,157（6）：717-724.
[1０] Morris DG,Kola B,Borboli N,et al. Identification of adrenocor-ticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas[J]. J Clin Endocrinol Metab,2003,88（12）：6080-6087.
[11] Ebisawa T,Tojo K,Tajima N,et al.Immunohistochemical analysis of 11-beta-hydroxysteroid dehydrogenase type 2 and glucocorticoid receptor in subclinical Cushing's disease due to pituitary macroadenoma[J]. Endocr Pathol,2008,19（4）：252-260.
[12] Luque RM,Ibá?觡ez-Costa A,López-Sánchez LM,et al. A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients：key role of AVPR1b receptor and potential therapeutic implications[J]. J Clin Endocrinol Metab,2013,98（10）：4160-4169.
[13] Wang FF,Tang KT,Yen YS,et al. Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2,but not with that of vasopressin receptor 1 or 3,in their pituitary tumours[J]. Clin Endocrinol（Oxf）,2012,76（2）：253-263
[14] Ben-Shlomo A,Schmid H,Wawrowsky K,et al. Differential ligand-mediated pituitary somatostatin receptor subtype signal-ing：implications for corticotroph tumor therapy[J]. J Clin Endocrinal Metab,2009,94（11）：4342-4350.
[15] Colao A,Petersenn S,Newell-Price J,et al. A 12-month phase 3 study of pasireotide in Cushing's disease[J]. N Engl J Med,2012,
366（10）：914-924.
[16] Pivonello R,Ferone D,de Herder WW,et al. Dopamine receptor expression and function in corticotroph pituitary tumors[J]. J Clin Endocrinol Metab,2004,89（5）：2452-2462.
[17] Pivonello R,De Martino MC,Cappabianca P,et al. The medical treatment of Cushing's disease：effectiveness of chronic treat-ment with the dopamine agonist cabergoline in patients unsuc-cessfully treated by surgery[J]. J Clin Endocrinol Metab,2009,
94（1）：223-230.
[18] de Bruin C,Pereira AM,Feelders RA,et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas[J]. J Clin Endocrinal Metab,2009,94（4）：1118-1124.
[19] Feelders RA,de Bruin C,Pereira AM,et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease[J]. N Engl J Med,2010,362（19）：1846-1848.
[2０] Matsumoto S,Hashimoto K,Yamada M,et al. Liver X receptor-alpha regulates proopiomelanocortin （POMC） gene transcription in the pituitary[J]. Mol Endocrinol,2009,23（1）：47-60.
[21] Hashimoto K,Matsumoto S,Ishida E,et al. Liver X receptor-alpha/beta expression ratio is increased in ACTH-secreting pituitary adenomas[J]. Neurosci Lett,2011,494（1）：34-37.
[22] Du L,Bergsneider M,Mirsadraei L,et al. Evidence for orphan nuclear receptor TR4 in the etiology of Cushing disease[J]. Proc Natl Acad Sci U S A,2013,110（21）：8555-8560.
[23] Giacomini D,Páez-Pereda M,Theodoropoulou M,et al.Bone morphogenetic protein-4 inhibits corticotroph tumor cells：invo-
lvement in the retinoic acid inhibitory action[J]. Endocrinology,2006,147 （1）：247-256.
[24] Tsukamoto N,Otsuka F,Miyoshi T,et al. Effects of bone morphogenetic protein （BMP） on adrenocorticotropin production by pituitarycorticotrope cells：involvement of up-regulation of BMP receptor signaling by somatostatin analogs[J]. Endocrinology, 2010,151（3）：1129-1141.